Cytogen Statistics

Total Valuation

Cytogen has a market cap or net worth of KRW 107.85 billion. The enterprise value is 78.27 billion.

Market Cap	107.85B
Enterprise Value	78.27B

Important Dates

The next estimated earnings date is Monday, March 17, 2025.

Earnings Date	Mar 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Cytogen has 23.07 million shares outstanding. The number of shares has increased by 20.02% in one year.

Current Share Class	n/a
Shares Outstanding	23.07M
Shares Change (YoY)	+20.02%
Shares Change (QoQ)	+1.36%
Owned by Insiders (%)	18.32%
Owned by Institutions (%)	0.03%
Float	11.72M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	16.31
PB Ratio	1.85
P/TBV Ratio	2.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.89
EV / Sales	12.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.51

Financial Position

The company has a current ratio of 11.41, with a Debt / Equity ratio of 0.25.

Current Ratio	11.41
Quick Ratio	10.76
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	-1.40
Interest Coverage	-5.92

Financial Efficiency

Return on equity (ROE) is -46.56% and return on invested capital (ROIC) is -15.82%.

Return on Equity (ROE)	-46.56%
Return on Assets (ROA)	-13.50%
Return on Capital (ROIC)	-15.82%
Revenue Per Employee	121.29M
Profits Per Employee	-313.68M
Employee Count	51
Asset Turnover	0.11
Inventory Turnover	7.25

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.28% in the last 52 weeks. The beta is 0.22, so Cytogen's price volatility has been lower than the market average.

Beta (5Y)	0.22
52-Week Price Change	-60.28%
50-Day Moving Average	5,539.50
200-Day Moving Average	8,240.68
Relative Strength Index (RSI)	42.27
Average Volume (20 Days)	57,120

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cytogen had revenue of KRW 6.19 billion and -16.00 billion in losses. Loss per share was -741.47.

Revenue	6.19B
Gross Profit	1.34B
Operating Income	-11.85B
Pretax Income	-16.48B
Net Income	-16.00B
EBITDA	-9.99B
EBIT	-11.85B
Loss Per Share	-741.47

Full Income Statement

Balance Sheet

The company has 44.50 billion in cash and 14.62 billion in debt, giving a net cash position of 29.89 billion or 1,295.58 per share.

Cash & Cash Equivalents	44.50B
Total Debt	14.62B
Net Cash	29.89B
Net Cash Per Share	1,295.58
Equity (Book Value)	58.50B
Book Value Per Share	2,522.65
Working Capital	46.37B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -9.57 billion and capital expenditures -844.08 million, giving a free cash flow of -10.42 billion.

Operating Cash Flow	-9.57B
Capital Expenditures	-844.08M
Free Cash Flow	-10.42B
FCF Per Share	-451.60

Full Cash Flow Statement

Margins

Gross margin is 21.59%, with operating and profit margins of -191.49% and -258.63%.

Gross Margin	21.59%
Operating Margin	-191.49%
Pretax Margin	-266.35%
Profit Margin	-258.63%
EBITDA Margin	-161.44%
EBIT Margin	-191.49%
FCF Margin	n/a

Dividends & Yields

Cytogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.02%
Shareholder Yield	-20.02%
Earnings Yield	-15.86%
FCF Yield	-9.66%

Stock Splits

The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.

Last Split Date	Sep 28, 2022
Split Type	Forward
Split Ratio	3

Scores

Cytogen has an Altman Z-Score of 4.71.

Altman Z-Score	4.71
Piotroski F-Score	n/a